Crystal Bioscience and Boehringer Ingelheim announce multiple target antibody discovery collaboration

Boehringer IngelheimCrystal Bioscience Inc. (Crystal) and Boehringer Ingelheim have entered into an agreement to collaborate on the discovery and development of therapeutic antibodies. Crystal Bioscience will apply its proprietary gel encapsulated microenvironment (GEM) and chicken immunization platforms to discover antibodies to multiple targets selected by Boehringer Ingelheim, with the goal of discovering different development candidates that may result in new or better therapies. Boehringer Ingelheim will have the option to conduct the further development and commercialization of the antibodies. Under the terms of the agreement, Crystal will receive an upfront technology access fee and research funding for each program, and may receive technical success fees, option exercise fees, and other downstream payments.

"We appreciate the confidence that Boehringer Ingelheim has placed in our team and technology following on the success of our prior work together. We are very pleased to have a partner with the depth and breadth of experience of Boehringer Ingelheim in the development of therapeutic products" said Robert J. Etches, President and CEO of Crystal Bioscience.

"Crystal is an innovative addition to our biotherapeutics efforts. Crystal can deliver monoclonal antibodies generated in chicken, which offer access to new target space. We are pleased to extend our relationship with this proven partner and technology" said Jeffrey Hanke, SVP Research and Global Head Biotherapeutics at Boehringer Ingelheim.

About Crystal Bioscience Inc.
Crystal Bioscience is a privately held company that was founded in 2008 to develop a world-class therapeutic antibody discovery engine using chickens. Its platform is "powered by evolution," exploiting the large phylogenetic distance between mammals and birds to generate a diverse array of antibodies to human targets that have proven intractable in mammalian and other discovery platforms. Crystal’s patented platform provides the unique ability to isolate monoclonal antibodies from immunized chickens, and can screen simultaneously for specificity and biological activity. It has led to the discovery of bioactive monoclonals directed against difficult targets, including GPCRs and ion channels. Chicken antibodies often recognize both human and mouse orthologs, which can simplify early stages of drug development where mouse disease models are used. The depth of screening provided by the GEM assay in combination with the breadth of the antibody repertoire in immunized birds provides access to an unparalleled source of affinity matured antibodies with therapeutic potential.

About Boehringer Ingelheim
The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 140 affiliates and more than 46,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel medications of high therapeutic value for human and veterinary medicine.

Social responsibility is a central element of Boehringer Ingelheim's culture. Involvement in social projects, caring for employees and their families, and providing equal opportunities for all employees form the foundation of the global operations. Mutual cooperation and respect, as well as environmental protection and sustainability are intrinsic factors in all of Boehringer Ingelheim's endeavors.

In 2012, Boehringer Ingelheim achieved net sales of about 14.7 billion euro. R&D expenditure in the business area Prescription Medicines corresponds to 22.5% of its net sales.

Most Popular Now

Novartis rises to second place in 2018 Access to M…

Novartis ranked second in the 2018 Access to Medicine Index (ATMi), up from 3rd place in 2016, in recognition of its long-standing efforts to improve worldwide access to ...

Sanofi builds focus on rare blood disorders and ca…

Some of the most serious unmet patient needs today are in the field of hematology. Rare blood disorders and blood-related cancers continue to be a major focus of research...

MSD is looking for a digital health solution to em…

MSD Lebanon is looking for an external partner to co-create a digital solution that helps oncologists to stay updated with relevant clinical content about cancer. The sol...

FDA approves new treatment for patients with acute…

The U.S. Food and Drug Administration today approved Daurismo (glasdegib) tablets to be used in combination with low-dose cytarabine (LDAC), a type of chemotherapy, for t...

Lilly submits New Drug Application to the FDA for …

Eli Lilly and Company (NYSE: LLY) has announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for lasmiditan for the acute...

New study reveals probiotics do not help children …

Probiotics are a multibillion-dollar industry with marketing claims of being an effective treatment for a multitude of ailments, including diarrhea. However, findings fro...

Merck and Pfizer provide update on avelumab in pla…

Merck and Pfizer Inc. (NYSE: PFE) today announced that the Phase III JAVELIN Ovarian 200 trial evaluating avelumab* alone or in combination with pegylated liposomal doxor...

U.S. FDA approves Larotrectinib, the first TRK inh…

The U.S. Food and Drug Administration (FDA) has approved larotrectinib, the first oral TRK inhibitor, under the brand name Vitrakvi®. The approval is for the treatment of...

FDA approves first treatment for Lambert-Eaton mya…

The U.S. Food and Drug Administration today approved Firdapse (amifampridine) tablets for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults. LEMS is a r...

Bristol-Myers Squibb awards "Golden Tickets…

Bristol-Myers Squibb Company (NYSE: BMY) and LabCentral, an innovative, shared laboratory space designed as a launchpad for life-sciences and biotech startups, today anno...

Alcon to highlight its vision, strategy and benefi…

Alcon, the eye care division of Novartis, will today hold its first Capital Markets Day for investors and analysts in relation to the previously-announced intention of No...

FDA grants breakthrough device designation to arti…

Bayer announced today that the U.S. Food and Drug Administration (FDA) granted Breakthrough Device Designation to the Artificial Intelligence Software for Chronic Thrombo...